Edition:
United States

People: Vanda Pharmaceuticals Inc (VNDA.O)

VNDA.O on Consolidated Issue listed on NASDAQ Global Market

15.60USD
2 Dec 2016
Change (% chg)

$0.10 (+0.65%)
Prev Close
$15.50
Open
$15.30
Day's High
$15.78
Day's Low
$15.20
Volume
383,594
Avg. Vol
782,304
52-wk High
$18.00
52-wk Low
$6.91

Watkins, H. Thomas 

Mr. H. Thomas Watkins serves as Independent Chairman of Vanda Pharmaceuticals Inc., since September 2006. Mr. Watkins served as the President and Chief Executive Officer of Human Genome Sciences, Inc. and as a member of its Board of Directors from 2004 until August 2012, when Human Genome Sciences, Inc. was acquired by GlaxoSmithKline. Prior to his tenure at Human Genome Sciences, Inc., Mr. Watkins served as President of TAP Pharmaceutical Products, Inc. Mr. Watkins previously held a series of executive positions over the course of nearly twenty years with Abbott Laboratories. Mr. Watkins also serves on the Board of Directors of Horizon Pharma plc (NASDAQ: HZNP), the Biotechnology Industry Organization (“BIO”), and served as Chair of the BIO Board of Directors from June 2011 until April 2013.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --